6-Thioguanine Treatment in Inflammatory Bowel Disease: A Critical Appraisal by a European 6-TG Working Party
Authors:
- N.K.H. de BoerNBN.K.H. de Boer
- W. ReinischWRW. Reinisch
- A. TemlATA. Teml
- A.A. van BodegravenABA.A. van Bodegraven
- M. SchwabMSM. Schwab
- M. LukasMLM. Lukas
- T. OchsenkühnTOT. Ochsenkühn
- W. PetritschWPW. Petritsch
- P. KnoflachPKP. Knoflach
- S. AlmerSAS. Almer
- S.W. van der MerweSMS.W. van der Merwe
- K.R. HerrlingerKHK.R. Herrlinger
- 1 April 2006
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 73 (1) , 25-31
Abstract
Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004, European experts applying 6-TG further on in IBD patients presented data on safety and efficacy of 6-TG. After thorough evaluation of its risk-benefit ratio, the group consented that 6-TG may still be considered as a rescue drug in stringently defined indications in IBD, albeit restricted to a clinical research setting. As a potential indication for administering 6-TG, we delineated the requirement for maintenance therapy as well as intolerance and/or resistance to aminosalicylates, azathioprine, 6-mercaptopurine, methotrexate and infliximab. Furthermore, indications are preferred in which surgery is thought to be inappropriate. The standard 6-TG dosage should not exceed 25 mg daily. Routine laboratory controls are mandatory in short intervals. Liver biopsies should be performed after 6–12 months, three years and then three-yearly accompanied by gastroduodenoscopy, to monitor for potential hepatotoxicity, including nodular regenerative hyperplasia (NRH) and veno-occlusive disease (VOD). Treatment with 6-TG must be discontinued in case of overt or histologically proven hepatotoxicity.Keywords
This publication has 37 references indexed in Scilit:
- Nodular Regenerative Hyperplasia and ThiopurinesLiver Transplantation, 2005
- ReplyGastroenterology, 2005
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2004
- Thioguanine‐nucleotides do not predict efficacy of tioguanine in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2004
- 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patientsEuropean Journal of Gastroenterology & Hepatology, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprineGut, 2001
- Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patientsJournal of Hepatology, 1991
- Portal hypertension secondary to azathioprine in myasthenia gravisPostgraduate Medical Journal, 1988
- Treatment of Ulcerative Colitis with AntimetabolitesBMJ, 1966